USANA Health Sciences (NYSE:USNA – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Volatility and Risk
USANA Health Sciences has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Earnings & Valuation
This table compares USANA Health Sciences and ARS Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| USANA Health Sciences | $925.26 million | 0.40 | $10.76 million | $0.55 | 36.54 |
| ARS Pharmaceuticals | $84.28 million | 9.64 | -$171.30 million | ($1.75) | -4.67 |
USANA Health Sciences has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 0.6% of USANA Health Sciences shares are owned by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares USANA Health Sciences and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| USANA Health Sciences | 1.16% | 6.75% | 4.86% |
| ARS Pharmaceuticals | -203.25% | -100.29% | -51.09% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for USANA Health Sciences and ARS Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| USANA Health Sciences | 1 | 0 | 0 | 1 | 2.50 |
| ARS Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
ARS Pharmaceuticals has a consensus target price of $28.25, indicating a potential upside of 245.35%. Given ARS Pharmaceuticals’ higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than USANA Health Sciences.
Summary
USANA Health Sciences beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About USANA Health Sciences
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
